SubHero Banner

Jemperli (dostarlimab) – New drug approval

April 22, 2021 - The FDA announced the approval of GlaxoSmithKline’s Jemperli (dostarlimab-gxly), for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatments with a platinum-containing regimen.

Download PDF